BioLargo Reports FY2024 Results: Assets $301M, Liabilities $293M
Ticker: BLGO · Form: 10-K · Filed: Mar 31, 2025 · CIK: 880242
Sentiment: neutral
Topics: financials, annual-report, balance-sheet
TL;DR
BioLargo's 2024 10-K shows $301M assets vs $293M liabilities. Stock closed at $0.19.
AI Summary
BioLargo, Inc. filed its 10-K for the fiscal year ending December 31, 2024, reporting total assets of $301,274,243 and total liabilities of $292,945,747. The company's fiscal year 2024 saw a slight increase in its stock price, closing at $0.19 on December 31, 2024. BioLargo operates in the Chemicals & Allied Products sector.
Why It Matters
This filing provides a comprehensive overview of BioLargo's financial health and operational status for the past fiscal year, crucial for investors and stakeholders to assess the company's performance and future prospects.
Risk Assessment
Risk Level: medium — The company has significant liabilities relative to its assets, indicating potential financial strain.
Key Numbers
- $301.3B — Total Assets (Represents the company's total resources as of December 31, 2024.)
- $292.9B — Total Liabilities (Represents the company's total obligations as of December 31, 2024.)
- $0.19 — Stock Price (Closing price on December 31, 2024, indicating market valuation.)
Key Players & Entities
- BIOLARGO, INC. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- $301,274,243 (dollar_amount) — Total assets as of December 31, 2024
- $292,945,747 (dollar_amount) — Total liabilities as of December 31, 2024
- $0.19 (dollar_amount) — Closing common stock price on December 31, 2024
FAQ
What was BioLargo's net income or loss for the fiscal year ended December 31, 2024?
The provided snippet does not contain specific net income or loss figures for the fiscal year ended December 31, 2024. It focuses on asset and liability totals.
What are the primary business segments or products of BioLargo, Inc.?
BioLargo, Inc. is classified under the 'CHEMICALS & ALLIED PRODUCTS' SIC code [2800], suggesting its primary business involves chemical manufacturing or related products.
What was the company's cash position at the end of the fiscal year 2024?
The filing snippet does not explicitly state the cash and cash equivalents for the fiscal year ended December 31, 2024.
Has BioLargo undergone any name changes in its history?
Yes, BioLargo, Inc. has had previous names including NUWAY MEDICAL INC, NUWAY ENERGY INC, and LATIN AMERICAN CASINOS INC, with name changes occurring in 2003, 2001, and 1996 respectively.
What is the authorized number of common shares for BioLargo, Inc.?
The filing indicates an authorized number of 50,000,000 common shares.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 31, 2025 regarding BIOLARGO, INC. (BLGO).